193 related articles for article (PubMed ID: 36118157)
1. Nicotinamide Adenine Dinucleotide (NAD+) and Enkephalinase Inhibition (IV1114589NAD) Infusions Significantly Attenuate Psychiatric Burden Sequalae in Substance Use Disorder (SUD) in Fifty Cases.
Blum K; Han D; Baron D; Kazmi S; Elman I; Gomez LL; Gondre-Lewis MC; Thanos PK; Braverman ER; Badgaiyan RD
Curr Psychiatry Res Rev; 2022 Jul; 18(2):125-143. PubMed ID: 36118157
[TBL] [Abstract][Full Text] [Related]
2. Biotechnical development of genetic addiction risk score (GARS) and selective evidence for inclusion of polymorphic allelic risk in substance use disorder (SUD).
Blum K; Bowirrat A; Baron D; Lott L; Ponce JV; Brewer R; Siwicki D; Boyett B; Gondre-Lewis MC; Smith DE; Panayotis K T; Badgaiyan S; Hauser M; Fried L; A R; Downs BW; Badgaiyan RD
J Syst Integr Neurosci; 2020 Aug; 6(2):. PubMed ID: 33614164
[TBL] [Abstract][Full Text] [Related]
3. A Review of DNA Risk Alleles to Determine Epigenetic Repair of mRNA Expression to Prove Therapeutic Effectiveness in Reward Deficiency Syndrome (RDS): Embracing "Precision Behavioral Management".
Blum K; Steinberg B; Gondre-Lewis MC; Baron D; Modestino EJ; Badgaiyan RD; Downs BW; Bagchi D; Brewer R; McLaughlin T; Bowirrat A; Gold M
Psychol Res Behav Manag; 2021; 14():2115-2134. PubMed ID: 34949945
[TBL] [Abstract][Full Text] [Related]
4. The Future is Now for Precision Genomic Addiction Medicine as a Frontline Modality for Inducing "Dopamine Homeostasis" in Reward Deficiency Syndrome (RDS).
Gilley ED; Bowirrat A; Gupta A; Giordano J; A Dennen C; R Braverman E; D Badgaiyan R; McLaughlin T; Baron D; Blum K
Curr Pharm Biotechnol; 2023 Apr; ():. PubMed ID: 37102488
[TBL] [Abstract][Full Text] [Related]
5. The Benefits of Genetic Addiction Risk Score (GARS
Blum K; Modestino EJ; Gondre-Lewis M; Chapman EJ; Neary J; Siwicki D; Baron D; Hauser M; Smith DE; Roy AK; Thanos PK; Steinberg B; McLaughlin T; Fried L; Barh D; Dunston GA; Badgaiyan RD
Int J Genom Data Min; 2018; 2018(1):. PubMed ID: 30198022
[TBL] [Abstract][Full Text] [Related]
6. A Novel Precision Approach to Overcome the "Addiction Pandemic" by Incorporating Genetic Addiction Risk Severity (GARS) and Dopamine Homeostasis Restoration.
Blum K; Kazmi S; Modestino EJ; Downs BW; Bagchi D; Baron D; McLaughlin T; Green R; Jalali R; Thanos PK; Elman I; Badgaiyan RD; Bowirrat A; Gold MS
J Pers Med; 2021 Mar; 11(3):. PubMed ID: 33809702
[TBL] [Abstract][Full Text] [Related]
7. Lofexidine in Combination With Oral Naltrexone for Opioid Use Disorder Relapse Prevention: A Pilot Randomized, Double-Blind, Placebo-Controlled Study.
Hermes G; Hyman SM; Fogelman N; Kosten TR; Sinha R
Am J Addict; 2019 Nov; 28(6):480-488. PubMed ID: 31448846
[TBL] [Abstract][Full Text] [Related]
8. Novel Opipramol-Baclofen Combination Alleviates Depression and Craving and Facilitates Recovery From Substance Use Disorder-An Animal Model and a Human Study.
Bareli T; Ahdoot HL; Ben Moshe H; Barnea R; Warhaftig G; Gispan I; Maayan R; Rosca P; Weizman A; Yadid G
Front Behav Neurosci; 2021; 15():788708. PubMed ID: 35002647
[TBL] [Abstract][Full Text] [Related]
9. Pro-Dopamine Regulator (KB220) A Fifty Year Sojourn to Combat Reward Deficiency Syndrome (RDS): Evidence Based Bibliography (Annotated).
Kenneth B; Edward MJ; Marjorie GLC; David B; Bruce S; Panayotis TK; William DB; Davis S; Lisa L; Eric BR; Mark M; David M; Lyle F; Rajendra BD
CPQ Neurol Psychol; 2018; 1(2):. PubMed ID: 30957097
[TBL] [Abstract][Full Text] [Related]
10. Beyond Mor: Can Induction of Dopamine Homeostasis Along with Electrotherapy Attenuate the Opioid Crisis?
Blum K; Bowirrat A; Braverman ER; Dennen C; Zeine F; Jafari N; Sunder K; Thanos PK; Baron D; Barh D; Gupta A; Bagchi D; Gold MS; Badgaiyan RD
Clin Exp Psychol; 2023 Mar; 9(2):1-3. PubMed ID: 37363693
[TBL] [Abstract][Full Text] [Related]
11. Extraction and Quantitation of Nicotinamide Adenine Dinucleotide Redox Cofactors.
Lu W; Wang L; Chen L; Hui S; Rabinowitz JD
Antioxid Redox Signal; 2018 Jan; 28(3):167-179. PubMed ID: 28497978
[TBL] [Abstract][Full Text] [Related]
12. Molecular neurological correlates of endorphinergic/dopaminergic mechanisms in reward circuitry linked to endorphinergic deficiency syndrome (EDS).
Blum K; Baron D; McLaughlin T; Gold MS
J Neurol Sci; 2020 Apr; 411():116733. PubMed ID: 32088516
[TBL] [Abstract][Full Text] [Related]
13. Genetic Addiction Risk Score (GARS): molecular neurogenetic evidence for predisposition to Reward Deficiency Syndrome (RDS).
Blum K; Oscar-Berman M; Demetrovics Z; Barh D; Gold MS
Mol Neurobiol; 2014 Dec; 50(3):765-96. PubMed ID: 24878765
[TBL] [Abstract][Full Text] [Related]
14. Treatment of substance use disorders: Effects on patients with higher or lower levels of PTSD symptoms.
Wieferink CEM; de Haan HA; Dijkstra BAG; Fledderus M; Kok T
Addict Behav; 2017 Nov; 74():122-126. PubMed ID: 28622616
[TBL] [Abstract][Full Text] [Related]
15. Hypothesizing That Neuropharmacological and Neuroimaging Studies of Glutaminergic-Dopaminergic Optimization Complex (KB220Z) Are Associated With "Dopamine Homeostasis" in Reward Deficiency Syndrome (RDS).
Blum K; Febo M; Fried L; Li M; Dushaj K; Braverman ER; McLaughlin T; Steinberg B; Badgaiyan RD
Subst Use Misuse; 2017 Mar; 52(4):535-547. PubMed ID: 28033474
[TBL] [Abstract][Full Text] [Related]
16. Reward Deficiency Syndrome (RDS): A Cytoarchitectural Common Neurobiological Trait of All Addictions.
Blum K; Bowirrat A; Braverman ER; Baron D; Cadet JL; Kazmi S; Elman I; Thanos PK; Badgaiyan RD; Downs WB; Bagchi D; Llanos-Gomez L; Gold MS
Int J Environ Res Public Health; 2021 Nov; 18(21):. PubMed ID: 34770047
[TBL] [Abstract][Full Text] [Related]
17. Baseline patterns of substance use disorder severity and depression and anxiety symptoms moderate the efficacy of mindfulness-based relapse prevention.
Roos CR; Bowen S; Witkiewitz K
J Consult Clin Psychol; 2017 Nov; 85(11):1041-1051. PubMed ID: 29083220
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
19. Anhedonia, depression, anxiety, and craving in opiate dependent patients stabilized on oral naltrexone or an extended release naltrexone implant.
Krupitsky E; Zvartau E; Blokhina E; Verbitskaya E; Wahlgren V; Tsoy-Podosenin M; Bushara N; Burakov A; Masalov D; Romanova T; Tyurina A; Palatkin V; Yaroslavtseva T; Pecoraro A; Woody G
Am J Drug Alcohol Abuse; 2016 Sep; 42(5):614-620. PubMed ID: 27436632
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
